Department of Pharmacology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Pharmacology, Faculty of Pharmacy, Zagazig University, Egypt.
Department of Pharmacology, Faculty of Pharmacy, Zagazig University, Egypt.
Biomed Pharmacother. 2018 Apr;100:381-387. doi: 10.1016/j.biopha.2018.02.033. Epub 2018 Feb 16.
Despite the reported reduction in blood pressure in hypertensive patients treated with allopurinol, the mechanism of the allopurinol hypotensive effect is still unclear. In the current study, the hypotensive effect of allopurinol has been fully investigated in hypertensive rats. Hypertension was induced in rats by angiotensin II (120 ng/min/kg) infusion for two weeks. Rats were then subjected to real-time recording of blood pressure, left ventricular pressure and volume and surface ECG. After 10 min of basal recording, allopurinol was slowly injected into the femoral vein with a dose of 10 μmole/kg. Then, invasive blood pressure, cardiac hemodynamics and ECG were continuously recorded for an additional 20 min. In addition, the vasodilation effect of allopurinol was studied using the isolated artery technique. Allopurinol injection reduced systolic, diastolic and pulse blood pressure. Allopurinol suppressed both cardiac systolic and diastolic hemodynamics as is apparent from the reduction in the rate of rise and the rate of fall in left ventricular pressure. Allopurinol reduced the general cardiac output quickly. Allopurinol addition to the organ bath (10-1000 μM) produced significant vasodilation of PE pre-constricted aortae that was not affected by endothelium denudation, L-NAME or indomethacin. However, allopurinol ameliorated the calcium induced contraction of aorta pre-constricted with KCl in calcium-free media. Erk or ROCK inhibition did not attenuated allopurinol produced vasodilation. In conclusion, allopurinol has an antihypertensive effect that is mediated, probably, by reducing cardiac output and decreasing vascular resistance. The vasodilator effect of allopurinol is most likely mediated by calcium blocking activities.
尽管已有报道称别嘌醇可降低高血压患者的血压,但别嘌醇降压作用的机制仍不清楚。在本研究中,我们充分研究了别嘌醇在高血压大鼠中的降压作用。通过向大鼠输注血管紧张素 II(120ng/min/kg)持续两周诱导高血压。然后,对大鼠进行实时血压、左心室压力和容积及体表心电图记录。在基础记录 10 分钟后,缓慢向股静脉注射别嘌醇(剂量为 10μmole/kg)。然后,持续记录侵入性血压、心脏血流动力学和心电图 20 分钟。此外,我们还使用离体动脉技术研究了别嘌醇的血管舒张作用。别嘌醇注射降低了收缩压、舒张压和脉压。别嘌醇抑制了心脏的收缩和舒张血流动力学,表现为左心室压力上升和下降率降低。别嘌醇迅速降低总体心输出量。向器官浴槽中加入别嘌醇(10-1000μM)可显著舒张预先收缩的 PE 缩窄的主动脉,而内皮细胞剥脱、L-NAME 或吲哚美辛对其无影响。然而,别嘌醇可改善 KCl 预收缩的无钙介质中由钙诱导的主动脉收缩。Erk 或 ROCK 抑制并不能减弱别嘌醇产生的血管舒张作用。总之,别嘌醇具有降压作用,可能是通过降低心输出量和降低血管阻力来介导的。别嘌醇的血管舒张作用很可能是通过钙阻断活动介导的。